LipoRed - Munich BiotechAlternative Names: LipoRed
Latest Information Update: 15 Sep 2015
At a glance
- Originator Munich Biotech (CEASED)
- Class Antivirals
- Mechanism of Action Diagnostic imaging enhancers
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 13 Feb 2004 Phase-I/II clinical trials in Solid tumour diagnosis in Germany (IV)